Topical treatment of field cancerization

Cancer Treatment and Research

Volumn 146, Issue , 2009, Pages 439-446

  Ulrich, Claas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; DICLOFENAC; FLUOROURACIL; IMIQUIMOD; PLACEBO; AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ACTINIC KERATOSIS; APPLICATION SITE BURNING; APPLICATION SITE EDEMA; APPLICATION SITE EROSION; APPLICATION SITE ERYTHEMA; APPLICATION SITE INFLAMMATION; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; APPLICATION SITE STINGING; BASAL CELL CARCINOMA; BOWEN DISEASE; CANCER GROWTH; CAUTERIZATION; CLINICAL TRIAL; CRYOTHERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSPLASIA; EPIDERMAL DYSPLASIA; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; LOW LEVEL LASER THERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PAIN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; SKIN CANCER; SKIN CARCINOGENESIS; SQUAMOUS CELL CARCINOMA; TOPICAL TREATMENT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; IMMUNOSUPPRESSIVE TREATMENT; KERATOSIS, ACTINIC; ORGAN TRANSPLANTATION; PHOTOCHEMOTHERAPY; PROCEDURES; RECURRENT DISEASE; SKIN NEOPLASMS; TISSUE DISTRIBUTION;

AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; DICLOFENAC; FLUOROURACIL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KERATOSIS, ACTINIC; ORGAN TRANSPLANTATION; PHOTOCHEMOTHERAPY; RECURRENCE; SKIN NEOPLASMS; TISSUE DISTRIBUTION;

EID: 77952683171     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-78574-5_36     Document Type: Review

References (35)

1. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium. Cancer 1953; 6:963-8.
2. Hitt R, Echarri MJ. Molecular biology in head and neck cancer. Clin Transl Oncol 2006; 8:776-9.
3. Boyle J,MacKie RM, Briggs JD, Junor BJ, Aitchison TC. Cancer, warts, and sunshine in renal transplant patients. A case-control study. Lancet 1984; 1:702-5.
4. Parrish JA. Immunosuppression, skin cancer, and ultraviolet A radiation. N Engl J Med 2005; 353:2712-3.
5. Testerman TL, Gerster JF, Imbertson LM et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol 1995; 58:365-72.
6. Hemmi H, Kaisho T, Takeuchi O et al. Small antiviral compounds activate immune cells via the TLR7MyD88-dependent signal pathway. Nat Immunol 2002; 3:196-200, 211, 212.
7. Lebwohl M, Dinehart S, Whiting D, Lee P, Tawfik N, Jorizzo J, Lee J, Fox T. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, doubleblind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004; 50:714-21.
8. Stockfleth E, Christophers E, Benninghoff B, SterryW. Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. Arch Dermatol 2004; 140:1542.
9. Vidal D, Alomar A. Efficacy of imiquimod 5% cream for basal cell carcinoma in transplant patients. Clin Exp Dermatol 2004; 29:237-239.
10. Brown VL, Atkins CL, Ghali L, Cerio R, Harwood CA, Proby CM. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial. Arch Dermatol 2005; 141:985-93.
11. Ulrich C, Hackethal M, Ulrich M, Howorka A, Forschner T, Sterry W, Stockfleth E. Treatment of multiple actinic keratoses with topical diclofenac 3% gel in organ transplant recipients: a series of six cases. Br J Dermatol 2007;Suppl 3:40-2.
12. Ulrich C, Bichel J, Euvrard S, Guidi B, Proby CM, van de Kerkhof PCM, Amerio P, Rønnevig J, Slade HB, Stockfleth E. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5%cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol 2007; 157(Suppl 2):25-31.
13. Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry E, Stockfleth E. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007; 157(Suppl 2):34-40.
14. Wolfe CM, Tafuri N, Hatfield K. Exacerbation of myasthenia gravis during imiquimod treatment. J Drugs Dermatol 2007; 6:745-6.
15. Sidoroff A. Photodynamic therapy of cutaneous epithelial malignancies. An evidence-based review. Hautarzt 2007; 58:577-84.
16. Wulf HC, Pavel S, Stender I, Bakker-Wensveen CA. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta Dermatol Venereol 2006; 86:25-8.
17. Dragieva G, Prinz BM, Hafner J, Dummer R et al. A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br J Dermatol 2004; 151:196-200.
18. de Graaf YG, Kennedy C, Wolterbeek R et al. Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ-transplant recipients: results of a randomizedcontrolled trial. J Invest Dermatol 2006; 126:569-74.
19. Dragieva G, Hafner J, Dummer R et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation 2004; 77:1-6.
20. Perrett CM, McGregor JM, Warwick J et al. Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br J Dermatol 2007; 156:320-8.
21. Eaglstein WH, Weinstein GD, Frost P. Fluorouracil: mechanism of action in human skin and actinic keratoses. I. Effect on DNA synthesis in vivo. Arch Dermatol 1970; 101:132-9.
22. Smith KJ, Germain M, Skelton H. Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol Surg 2001; 27:561-4.
23. Fisher SM. Is cyclooxygenase-2 important in skin carcinogenesis? J Environ Pathol Toxicol Oncol 2002; 21:183-91.
24. Buckmann SY, Gresham A, Hale P et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998; 19:723-9.
25. Kagoura M, Toyoda M, Masuri C, Morohashi M. Immunohistochemical expression of cyclooxygenase-2 in skin cancers. J Cutan Pathol 2001; 28:298-302.
26. Nijsten T, Colpaert CG, Vermeulen PB, Harris AL, VanMarck E, Lambert J. Cyclooxygenase- 2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases. Br J Dermatol 2004; 151:837-45.
27. William CS, Tsujii M, Reese J, Dey SK, DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000; 105:1589-94.
28. Gallo O, Franchi A, Magnelli L et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer: implications for tumour angiogenesis and metastasis. Neoplasia 2001; 3:53-61.
29. Dannenberg AJ, Altorki NK, Boyle JO, Lin DT, Subbaramaniah K. Inhibition of cyclooxygenase-2: an approach to preventing cancers of the upper aerodigestive tract. Ann N Y Acad Sci 2001; 952:109-15.
30. Cortes R. Correspondence. Int J Dermatol 2002; 44:371-3.
31. Rivers JK, Arlette J, Shear N et al. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 2002; 146:94-100.
32. Seed MP, Brown JR, Freemantle CN et al. The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan. Cancer Res 1997; 57:1625-9.
33. Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5 % fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 1992; 24:990-1000.
34. Ulrich C, Hackethal M, Ulrich M, Howorka A, Forschner T, Sterry W, Stockfleth E. Treatment of multiple actinic keratoses with topical diclofenac 3% gel in organ transplant recipients: a series of six cases. Br J Dermatol 2007; 156(Suppl 3):40-2.
35. Ulrich C, Johannsen A, Hackethal M, Ulrich M, SterryW, Stockfleth E. Treatment of multiple actinic keratoses with topical diclofenac 3% gel in organ transplant patients. (in preparation).